Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H (HK:2315)
:2315
Want to see HK:2315 full AI Analyst Report?
Top Page
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H
(2315)
Select Model
Select Model
Rating:58Neutral
Price Target:
HK$58.00
▲(102.09% Upside)
Action:Reiterated
Date:04/29/26
The score is primarily supported by improved fundamentals (profitability and positive cash generation) and a healthier leverage profile. This is tempered by an expensive valuation (high P/E) and mixed technicals, with the stock trading below key short-term moving averages despite neutral momentum indicators.
Positive Factors
Revenue scale & unit economics
Multi-year revenue scaling and persistently high gross margins indicate durable unit economics for Biocytogen's antibody discovery and preclinical services. A large revenue base and strong margins support reinvestment in platform R&D and make core services profitable across cycles, underpinning long-term cash generation if client demand remains stable.
Negative Factors
Earnings volatility history
A recent history of multi-year losses highlights that profitability is newly achieved and could be cyclical. Biotech services and milestone-driven revenue are subject to client program timing and partnership cadence; a reversion to prior loss profiles remains a realistic risk unless revenue and margin trends sustain across multiple quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue scale & unit economics
Multi-year revenue scaling and persistently high gross margins indicate durable unit economics for Biocytogen's antibody discovery and preclinical services. A large revenue base and strong margins support reinvestment in platform R&D and make core services profitable across cycles, underpinning long-term cash generation if client demand remains stable.
Read all positive factors
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H (2315) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$20.67B
Dividend YieldN/A
Average Volume (3M)488.12K
Price to Earnings (P/E)25.3
Beta (1Y)1.14
Revenue Growth48.38%
EPS GrowthN/A
CountryHK
Employees1,117
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)0.43
Shares Outstanding110,781,920
10 Day Avg. Volume755,126
30 Day Avg. Volume488,121
Financial Highlights & Ratios
PEG Ratio0.18
Price to Book (P/B)5.83
Price to Sales (P/S)9.20
P/FCF Ratio44.91
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.73
Revenue Forecast (FY)HK$1.89B
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H Business Overview & Revenue Model
Company Description
Biocytogen Pharmaceuticals (Beijing) Co., Ltd., a biotechnology company, engages in the research and development of antibody-based drugs worldwide. The company's pipeline includes 12 core products, among which two products are in Phase II multi-re...
How the Company Makes Money
Biocytogen primarily makes money by providing antibody discovery and related preclinical R&D services to pharmaceutical and biotech customers, leveraging its proprietary genetically engineered animal models to generate and screen therapeutic antib...
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H Financial Statement Overview
Summary
Income Statement
72
Positive
Balance Sheet
70
Positive
Cash Flow
66
Positive
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 1.38B | 980.45M | 716.91M | 533.88M | 354.56M |
| Gross Profit | 1.05B | 761.52M | 506.03M | 391.75M | 247.44M |
| EBITDA | 419.49M | 303.80M | -97.87M | -465.86M | -378.12M |
| Net Income | 173.20M | 33.54M | -382.95M | -602.16M | -545.58M |
Balance Sheet | |||||
| Total Assets | 3.72B | 2.42B | 2.45B | 2.80B | 2.30B |
| Cash, Cash Equivalents and Short-Term Investments | 1.56B | 381.18M | 408.09M | 611.27M | 566.45M |
| Total Debt | 584.09M | 570.28M | 544.11M | 415.28M | 89.80M |
| Total Liabilities | 1.54B | 1.58B | 1.66B | 1.65B | 1.05B |
| Stockholders Equity | 2.17B | 834.06M | 785.89M | 1.15B | 1.25B |
Cash Flow | |||||
| Free Cash Flow | 282.43M | 174.12M | -203.26M | -543.94M | -564.45M |
| Operating Cash Flow | 370.25M | 211.25M | -76.65M | -303.27M | -365.78M |
| Investing Cash Flow | -184.86M | -137.12M | -100.28M | -153.74M | -84.13M |
| Financing Cash Flow | 979.86M | -92.03M | -37.82M | 587.20M | 219.44M |
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H Technical Analysis
Positive
28.70
Price Trends
55.34
Negative
49.04
Positive
37.94
Positive
Market Momentum
-1.62
Positive
45.20
Neutral
26.18
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2315, the sentiment is Positive. The current price of 28.7 is below the 20-day moving average (MA) of 52.80, below the 50-day MA of 55.34, and below the 200-day MA of 37.94, indicating a neutral trend. The MACD of -1.62 indicates Positive momentum. The RSI at 45.20 is Neutral, neither overbought nor oversold. The STOCH value of 26.18 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:2315.
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
58 Neutral | HK$20.67B | 25.33 | 11.29% | ― | 48.38% | ― | |
58 Neutral | HK$17.22B | -8.22 | -17.26% | ― | 66.66% | 6.11% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | HK$7.99B | 9.33 | 24.17% | ― | 154.21% | ― | |
49 Neutral | HK$10.20B | -75.25 | -11.81% | ― | 219.26% | 87.63% | |
47 Neutral | HK$15.76B | -27.65 | -18.69% | ― | 57.92% | -23.76% |
* Healthcare Sector Average
HK:2315
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H
50.60
36.32
254.34%
HK:1672
Ascletis Pharma, Inc.
14.85
7.85
112.14%
HK:2157
Lepu Biopharma Co. Ltd. Class H
4.43
-0.04
-0.89%
HK:2162
Keymed Biosciences, Inc.
61.35
19.15
45.38%
HK:2171
CARsgen Therapeutics Holdings Ltd.
17.63
-3.97
-18.38%
HK:6955
Shandong Boan Biotechnology Company., Limited. Class H
6.32
-4.68
-42.55%
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H Corporate Events
Biocytogen Clarifies AGM Resolution on RMB1.5 Billion Credit Facilities and Guarantees
May 7, 2026
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. has issued a clarification regarding a clerical error in its recent AGM circular, correcting the wording of a special resolution on proposed comprehensive credit facilities and guarantees for the compa...
Biocytogen issues unaudited Q1 2026 report and cautions investors
Apr 27, 2026
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. has published its unaudited first quarterly report for the three months ended March 31, 2026, prepared under PRC accounting principles for the STAR Market of the Shanghai Stock Exchange. The Hong Kong...
Biocytogen Sets 2025 AGM to Decide Profit Plan, Capital Changes and Credit Facilities
Apr 23, 2026
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. has convened its 2025 annual general meeting for May 21, 2026, to be held both physically in Beijing and virtually online. Shareholders will review the board’s 2025 work report and vote on reappo...
Biocytogen Sets April Board Meeting to Approve First-Quarter 2026 Results
Apr 15, 2026
Biocytogen Pharmaceuticals (Beijing) Co., Ltd., a Hong Kong-listed biopharmaceutical company, announced that its board includes a mix of executive, non-executive, independent non-executive, and employee directors. This governance structure is desi...
Biocytogen, Sihuan Form Strategic Alliance on Antibody Drugs and Weight-Loss Therapies
Apr 1, 2026
Biocytogen Pharmaceuticals has entered a strategic partnership with Sihuan Pharmaceutical Holdings Group to combine Biocytogen’s fully human antibody discovery and AI-driven platforms with Sihuan’s strengths in drug development, manufa...
Biocytogen Publishes Audited 2025 Results and Sets Timeline for Full Annual Report
Mar 26, 2026
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. has released its audited annual results for the year ended 31 December 2025, which have been reviewed by the board’s audit committee. The company stated that the annual results announcement inclu...
Biocytogen Partner NEOK Bio Wins FDA IND Clearance for Bispecific-Based ADC NEOK002
Mar 26, 2026
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. is a China-based biopharma developer specializing in fully human bispecific antibodies and related antibody-drug conjugates, underpinned by its RenLite platform that supports partnerships with external...
Biocytogen Updates Articles to Reflect STAR Market A-Share Listing and Expanded Capital
Mar 26, 2026
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. plans to amend its articles of association to formally reflect changes in its share capital following the issuance of 47,500,000 A shares and its listing on the STAR Market of the Shanghai Stock Excha...
Biocytogen Schedules Board Meeting to Approve 2025 Results and Consider Final Dividend
Mar 16, 2026
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. has scheduled a board meeting for 26 March 2026 to review and approve the audited annual results for the financial year ended 31 December 2025. The board will also deliberate on the potential declarat...
Biocytogen forecasts sharp 2025 profit surge on overseas growth and industry rebound
Feb 26, 2026
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. reported strong preliminary results for 2025, with total operating revenue rising 40.63% year on year to RMB1.38 billion and net profit attributable to shareholders surging more than fourfold to RMB17...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.